Table of Contents
Journal of Signal Transduction
Volume 2011, Article ID 635721, 7 pages
http://dx.doi.org/10.1155/2011/635721
Review Article

Regulation of Suppressors of Cytokine Signaling as a Therapeutic Approach in Autoimmune Diseases, with an Emphasis on Multiple Sclerosis

1Department of Cardiology, Yale Cardiovascular Research Center, Yale School of Medicine, New Haven, CT 16511, USA
2Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Received 29 June 2011; Accepted 9 September 2011

Academic Editor: Fred Schaper

Copyright © 2011 Vinod S. Ramgolam and Silva Markovic-Plese. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Sospedra and R. Martin, “Immunology of multiple sclerosis,” Annual Review of Immunology, vol. 23, pp. 683–747, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. B. Bielekova, B. Goodwin, N. Richert et al., “Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand,” Nature Medicine, vol. 6, no. 10, pp. 1167–1175, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. L. E. Harrington, R. D. Hatton, P. R. Mangan et al., “Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages,” Nature Immunology, vol. 6, no. 11, pp. 1123–1132, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. Amadi-Obi, C. R. Yu, X. Liu et al., “TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1,” Nature Medicine, vol. 13, no. 6, pp. 711–718, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. Matusevicius, P. Kivisäkk, B. He et al., “Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis,” Multiple Sclerosis, vol. 5, no. 2, pp. 101–104, 1999. View at Google Scholar · View at Scopus
  6. C. Lock, G. Hermans, R. Pedotti et al., “Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis,” Nature Medicine, vol. 8, no. 5, pp. 500–508, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. S. Tzartos, M. A. Friese, M. J. Craner et al., “Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis,” American Journal of Pathology, vol. 172, no. 1, pp. 146–155, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. Montes, X. Zhang, L. Berthelot et al., “Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells,” Clinical Immunology, vol. 130, no. 2, pp. 133–144, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. L. Durelli, L. Conti, M. Clerico et al., “T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β,” Annals of Neurology, vol. 65, no. 5, pp. 499–509, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. T. Carlson, M. Kroenke, P. Rao, T. E. Lane, and B. Segal, “The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease,” Journal of Experimental Medicine, vol. 205, no. 4, pp. 811–823, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. H. Kebir, K. Kreymborg, I. Ifergan et al., “Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation,” Nature Medicine, vol. 13, no. 10, pp. 1173–1175, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. H. Ogura, M. Murakami, Y. Okuyama et al., “Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction,” Immunity, vol. 29, no. 4, pp. 628–636, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. A. Yoshimura, T. Naka, and M. Kubo, “SOCS proteins, cytokine signalling and immune regulation,” Nature Reviews Immunology, vol. 7, no. 6, pp. 454–465, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R. Nakagawa, T. Naka, H. Tsutsui et al., “SOCS-1 participates in negative regulation of LPS responses,” Immunity, vol. 17, no. 5, pp. 677–687, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Kubo, T. Hanada, and A. Yoshimura, “Suppressors of cytokine signaling and immunity,” Nature Immunology, vol. 4, no. 12, pp. 1169–1176, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. K. C. Huang, C. W. Chen, J. C. Chen, and W. W. Lin, “Statins induce suppressor of cytokine signaling-3 in macrophages,” FEBS Letters, vol. 555, no. 2, pp. 385–389, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Jo, D. Liu, S. Yao, R. D. Collins, and J. Hawiger, “Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis,” Nature Medicine, vol. 11, no. 8, pp. 892–898, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. K. Vandenbroeck, J. Alvarez, B. Swaminathan et al., “A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis,” Genes and Immunity. In press. View at Publisher · View at Google Scholar · View at PubMed
  19. R. L. Zuvich, J. L. McCauley, J. R. Oksenberg et al., “Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility,” Human Genetics, vol. 127, no. 5, pp. 525–535, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. E. V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F. Sallusto, “Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells,” Nature Immunology, vol. 8, no. 9, pp. 942–949, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. Z. Chen, C. M. Tato, L. Muul, A. Laurence, and J. J. O'Shea, “Distinct regulation of interleukin-17 in human T helper lymphocytes,” Arthritis and Rheumatism, vol. 56, no. 9, pp. 2936–2946, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. N. J. Wilson, K. Boniface, J. R. Chan et al., “Development, cytokine profile and function of human interleukin 17-producing helper T cells,” Nature Immunology, vol. 8, no. 9, pp. 950–957, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. F. Annunziato, L. Cosmi, V. Santarlasci et al., “Phenotypic and functional features of human Th17 cells,” Journal of Experimental Medicine, vol. 204, no. 8, pp. 1849–1861, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. E. V. Acosta-Rodriguez, L. Rivino, J. Geginat et al., “Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells,” Nature Immunology, vol. 8, no. 6, pp. 639–646, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. L. H. Glimcher and K. M. Murphy, “Lineage commitment in the immune system: the T helper lymphocyte grows up,” Genes and Development, vol. 14, no. 14, pp. 1693–1711, 2000. View at Google Scholar · View at Scopus
  26. X. O. Yang, A. D. Panopoulos, R. Nurieva et al., “STAT3 regulates cytokine-mediated generation of inflammatory helper T cells,” Journal of Biological Chemistry, vol. 282, no. 13, pp. 9358–9363, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. R. Starr, T. A. Willson, E. M. Viney et al., “A family of cytokine-inducible inhibitors of signalling,” Nature, vol. 387, no. 6636, pp. 917–921, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. Naka, M. Narazaki, M. Hirata et al., “Structure and function of a new STAT-induced STAT inhibitor,” Nature, vol. 387, no. 6636, pp. 924–929, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. I. Kinjyo, T. Hanada, K. Inagaki-Ohara et al., “SOCS1/JAB is a negative regulator of LPS-induced macrophage activation,” Immunity, vol. 17, no. 5, pp. 583–591, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Chinen, T. Kobayashi, H. Ogata et al., “Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNγ and IL-4 are involved,” Gastroenterology, vol. 130, no. 2, pp. 373–388, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. E. Fenner, A. L. Cornish, J. G. Zhang et al., “Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity,” Nature Immunology, vol. 7, no. 1, pp. 33–39, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. Y. Qing, A. P. Costa-Pereira, D. Watling, and G. R. Stark, “Role of tyrosine 441 of interferon-γ receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation,” Journal of Biological Chemistry, vol. 280, no. 3, pp. 1849–1853, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. W. S. Alexander, R. Starr, J. E. Fenner et al., “SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine,” Cell, vol. 98, no. 5, pp. 597–608, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. J. C. Marine, D. J. Topham, C. McKay et al., “SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality,” Cell, vol. 98, no. 5, pp. 609–616, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Kinjyo, H. Inoue, S. Hamano et al., “Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-β1,” Journal of Experimental Medicine, vol. 203, no. 4, pp. 1021–1031, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. B. A. Croker, D. L. Krebs, J. G. Zhang et al., “SOCS3 negatively regulates IL-6 signaling in vivo,” Nature Immunology, vol. 4, no. 6, pp. 540–545, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. H. Yasukawa, M. Ohishi, H. Mori et al., “IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages,” Nature Immunology, vol. 4, no. 6, pp. 551–556, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. L. De Beaucoudtey, A. Puel, O. Filipe-Santos et al., “Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells,” Journal of Experimental Medicine, vol. 205, no. 7, pp. 1543–1550, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. C. S. Ma, G. Y. J. Chew, N. Simpson et al., “Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3,” Journal of Experimental Medicine, vol. 205, no. 7, pp. 1551–1557, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. Z. Chen, A. Laurence, Y. Kanno et al., “Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 21, pp. 8137–8142, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. C. T. Weaver, R. D. Hatton, P. R. Mangan, and L. E. Harrington, “IL-17 family cytokines and the expanding diversity of effector T cell lineages,” Annual Review of Immunology, vol. 25, pp. 821–852, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. G. Frisullo, M. Mirabella, F. Angelucci et al., “The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis,” Journal of Neuroimmunology, vol. 192, no. 1-2, pp. 174–183, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. V. S. Ramgolam, Y. Sha, J. Jin, X. Zhang, and S. Markovic-Plese, “IFN-β inhibits human Th17 cell differentiation,” Journal of Immunology, vol. 183, no. 8, pp. 5418–5427, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. V. S. Ramgolam, Y. Sha, K. L. Marcus et al., “B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis,” Journal of Immunology, vol. 186, no. 7, pp. 4518–4526, 2011. View at Publisher · View at Google Scholar · View at PubMed
  45. I. Teige, A. Treschow, A. Teige et al., “IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 170, no. 9, pp. 4776–4784, 2003. View at Google Scholar · View at Scopus
  46. K. P. Wandinger, P. Reissland, H. Kirchner, K. Wessel, and M. Otto, “Production of endogenous interferon-α and β in patients with multiple sclerosis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 64, no. 2, pp. 277–278, 1998. View at Google Scholar · View at Scopus
  47. G. C. Ebers, G. Rice, J. Lesaux et al., “Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis,” Lancet, vol. 352, no. 9139, pp. 1498–1504, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. A. A. Byrnes, J. C. McArthur, and C. L. Karp, “Interferon-β therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and Interleukin-10 production,” Annals of Neurology, vol. 51, no. 2, pp. 165–174, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. M. Krakauer, P. Sorensen, M. Khademi, T. Olsson, and F. Sellebjerg, “Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-β treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression,” Multiple Sclerosis, vol. 14, no. 5, pp. 622–630, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. M. Prinz, H. Schmidt, A. Mildner et al., “Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system,” Immunity, vol. 28, no. 5, pp. 675–686, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. B. Guo, E. Y. Chang, and G. Cheng, “The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice,” Journal of Clinical Investigation, vol. 118, no. 5, pp. 1680–1690, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. X. Zhang, J. Jin, Y. Tang, D. Speer, D. Sujkowska, and S. Markovic-Plese, “IFN-β1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation,” Journal of Immunology, vol. 182, no. 6, pp. 3928–3936, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. Y. Li, N. Chu, A. Hu, B. Gran, A. Rostami, and G. X. Zhang, “Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia,” Brain, vol. 130, no. 2, pp. 490–501, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. A. Vaknin-Dembinsky, K. Balashov, and H. L. Weiner, “IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production,” Journal of Immunology, vol. 176, no. 12, pp. 7768–7774, 2006. View at Google Scholar · View at Scopus
  55. H. Qin, C. A. Wilson, J. L. Sun, and E. N. Benveniste, “IFN-β-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia,” FASEB Journal, vol. 20, no. 7, pp. E118–E128, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. K. Tanaka, K. Ichiyama, M. Hashimoto et al., “Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-γ on STAT3 and Smads,” Journal of Immunology, vol. 180, no. 6, pp. 3746–3756, 2008. View at Google Scholar · View at Scopus
  57. H. Frobøse, S. G. Rønn, P. E. Heding et al., “Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex,” Molecular Endocrinology, vol. 20, no. 7, pp. 1587–1596, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. Y. Huang, J. J. Feld, R. K. Sapp et al., “Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C,” Gastroenterology, vol. 132, no. 2, pp. 733–744, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. Z. Liu, C. M. Pelfrey, A. Cotleur, J. C. Lee, and R. A. Rudick, “Immunomodulatory effects of interferon beta-1a in multiple sclerosis,” Journal of Neuroimmunology, vol. 112, no. 1-2, pp. 153–162, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. D. R. Wesemann, Y. Dong, G. M. O'Keefe, V. T. Nguyen, and E. N. Benveniste, “Suppressor of cytokine signaling 1 inhibits cytokine induction of CD40 expression in macrophages,” Journal of Immunology, vol. 169, no. 5, pp. 2354–2360, 2002. View at Google Scholar · View at Scopus
  61. M. Comabella, J. D. Lünemann, J. Río et al., “A type i interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis,” Brain, vol. 132, no. 12, pp. 3353–3365, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. B. Kwak, F. Mulhaupt, S. Myit, and F. Mach, “Statins as a newly recognized type of immunomodulator,” Nature Medicine, vol. 6, no. 12, pp. 1399–1402, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. A. Yilmaz, C. Reiss, O. Tantawi et al., “HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis,” Atherosclerosis, vol. 172, no. 1, pp. 85–93, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. S. S. Zamvil and L. Steinman, “Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS,” Neurology, vol. 59, no. 7, pp. 970–971, 2002. View at Google Scholar · View at Scopus
  65. T. Vollmer, L. Key, V. Durkalski et al., “Oral simvastatin treatment in relapsing-remitting multiple sclerosis,” Lancet, vol. 363, no. 9421, pp. 1607–1608, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. X. Zhang, J. Jin, X. Peng, V. S. Ramgolam, and S. Markovic-Plese, “Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes,” Journal of Immunology, vol. 180, no. 10, pp. 6988–6996, 2008. View at Google Scholar · View at Scopus
  67. X. Zhang, Y. Tao, J. Wang et al., “Simvastatin inhibits interferon regulatory factor 4 expression and Th17-cell differentiation in CD4 T-cells derived from patients with multiple sclerosis,” Journal of Immunology, vol. 187, pp. 3431–3437, 2011. View at Google Scholar
  68. S. Youssef, O. Stüve, J. O. Patarroyo et al., “The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease,” Nature, vol. 420, no. 6911, pp. 78–84, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. M. G. Mujtaba, L. O. Flowers, C. B. Patel, R. A. Patel, M. I. Haider, and H. M. Johnson, “Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form,” Journal of Immunology, vol. 175, no. 8, pp. 5077–5086, 2005. View at Google Scholar · View at Scopus